AJR Women's Imaging Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braeuning, M. P.
Right arrow Articles by Pisano, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braeuning, M. P.
Right arrow Articles by Pisano, E. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
AJR 2000; 174:251-252
© American Roentgen Ray Society


Technical Innovation

Embolization Coils as Tumor Markers for Mammography in Patients Undergoing Neoadjuvant Chemotherapy for Carcinoma

M. Patricia Braeuning, Eithne T. Burke and Etta D. Pisano

Department of Radiology, University of North Carolina at Chapel Hill, CB 7510, Chapel Hill, NC 27599-7510.

Received April 21, 1999; accepted after revision June 8, 1999.

 
Address correspondence to M.P. Braeuning.


Introduction
Top
Introduction
Subjects and Methods
Discussion
References
 
A recent approach in breast cancer therapy for patients with large primary tumors is the ause of "neoadjuvant" or primary chemotherapy. This involves treating patients with chemotherapy before definitive surgical therapy as opposed to traditional adjuvant chemotherapy, which is given after surgical therapy.

Serial physical examination, mammography, and sonography are important in assessing tumor response to chemotherapy. However, a problem that we have encountered is that in some patients response to chemotherapy is so good that no remaining physical or imaging evidence of the primary tumor remains. In these patients, the initial tumor bed must be localized by anatomic landmarks on the basis of prechemotherapy images. This may not be very precise and may impair the ability to assess for residual microscopic tumor. Patients with a good response to chemotherapy may also be candidates for breast conservation, so it is important that the exact tumor bed be excised. We have devised a method by which to mark the tumor bed with radiopaque markers before the institution of chemotherapy.


Subjects and Methods
Top
Introduction
Subjects and Methods
Discussion
References
 
Patients at our institution who will be undergoing neoadjuvant chemotherapy with the possibility of later breast conservation (stage T2 or T3 tumors) are eligible. After initial physical examination, mammographic and sonographic tumor measurements and a histologic diagnosis (usually via core needle biopsy) of invasive carcinoma are obtained, and the decision is made to mark the tumor bed. The multidisciplinary clinical team bases this decision on the probability that the patient will be a candidate for breast conservation if she has a good response after chemotherapy. We mark four sites around the tumor bed (medial, lateral, cephalad, and caudad) using radiopaque markers. The tumor is localized by sonography, if possible; however, if the tumor is not visible on sonography, stereotactic guidance can be used. To date, all tumors have been visible sonographically.

Initially, we used Hilal (MWCE-18-2.0-2-HILAL; Cook, Bloomington, IN) embolization microcoils. Since that time, Cook has developed another coil for this purpose (MCE-35P-1-2-VA; Cook), which is easier to introduce. The latter coils are made of platinum so that they do not interfere with breast MR imaging. Under imaging guidance and sterile conditions using lidocaine for anesthesia, the cephalad, caudad, medial, and lateral margins of the tumor are in turn localized and marked. The deep margin is not marked because the surgeons at our institution routinely remove tissue down to the pectoral fascia at the time of excision. The apex of the superficial margin is estimated by the surgeon at the time of excision. Localization under sonographic guidance is performed using a freehand technique similar to that used for a cyst aspiration. The apex or widest margin of the mass is identified and the coil deployed approximately 2 mm from the tumor edge. Under stereotactic guidance, the widest margin of the tumor should be targeted at the edge of the mass to determine the appropriate depth, but the coil should be placed approximately 2 mm away from and slightly past the visible edge of the tumor to ensure that its margins are encompassed. For sonographically guided deployment, an 18-gauge 7-cm-long vascular entry needle (SDN-18-7.0; Cook) is used. A longer 15-cm trocar version (DTN-18-15.0; Cook) can be used for stereotactic guidance.

The platinum coils deploy easily through an 18-gauge vascular entry needle. If the coil "catches" in the shaft of the vascular entry needle, it can be advanced into the breast using the needle stylet or a chasing bolus of sterile saline (Fig. 1A, Fig. 1B, Fig. 1C). The procedure has been well tolerated by patients.



View larger version (114K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1. —Examples of devices (Cook, Bloomington, IN).

A, Vascular entry needle (A), coil introducer (B), and "pusher" (C).

 


View larger version (105K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1. —Examples of devices (Cook, Bloomington, IN).

B, To deploy coil, vascular entry needle (A) is advanced to desired location in breast, introducer (B) is placed into back of needle, and pusher (C) is used to advance coil into needle. Stylet of vascular entry needle can then be used to ensure that coil has been advanced through needle into breast tissue. This is accomplished by replacing stylet back into sheath and advancing it down until original notches interlock.

 


View larger version (123K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1. —Examples of devices (Cook, Bloomington, IN).

C, 1 cm x 2 mm platinum coil.

 

After deployment of the coils, 90° lateral and craniocaudal mammograms are obtained as a baseline to document the exact location of the coils relative to the tumor. When the patient returns for follow-up mammograms after the second and fourth cycles of chemotherapy, the location of the coils can also be assessed, because as some of the tumors shrink the coils may draw closer together (Fig. 2). We have had no coils migrate after initial placement in the eight patients who have undergone this procedure to date. The complex shape of the coils likely deters migration.



View larger version (62K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2. —Baseline 90° lateral mammogram in 43-year-old woman. Coils placed around mammographically occult but sonographically visible infiltrating ductal carcinoma. Note that one coil did not "spring" back into tight coil.

 

At the time of definitive surgery, the four coils are marked with needle localization wires to resect the entire original tumor bed en bloc. The four localizing wires are placed from the shortest skin distance as in any standard localization. All wires can usually be placed from one projection. Unfortunately, the coils are not reproducibly visible on sonography; therefore, localizations are performed mammographically.


Discussion
Top
Introduction
Subjects and Methods
Discussion
References
 
Traditionally, the use of adjuvant chemotherapy has been based on the assumption that some tumors have higher risks of metastasis than others. In higher risk tumors, adjuvant chemotherapy is used to treat clinically occult micrometastases before they have a chance to disseminate into the rest of the body and mutate into more aggressive cell types. This therapy has proven to be effective in reducing long-term mortality [1, 2, 3]. Recently, this theory has been expanded: The sooner chemotherapy is instituted, the more vulnerable the cancer cells are likely to be to treatment and, therefore, the more effective the chemotherapy [4]. This should benefit long-term survival.

Clinical trials have shown that neoadjuvant chemotherapy is effective [4, 5, 6]. There are other theoretic advantages [6]. It enables direct assessment of the tumor's response to chemotherapy, which is an important prognostic indicator [7]. If the initial chemotherapeutic agent gives no response, the regimen can be changed. Also, the tumor may be down-staged so that less aggressive surgery may be feasible.

With neoadjuvant chemotherapy, the exact effect on tumor shrinkage is unpredictable. It has been shown that mammographic and physical examination findings after chemotherapy do not necessarily correlate with histologic findings [8]. Until this correlation can be predicted, the original tumor bed must be resected to ensure removal of microscopic disease. In addition to ensuring removal of the original tumor bed, the approach we describe will allow correlation of the mammographic appearance with the histologic appearance and may provide useful information in determining how large solid tumors are destroyed by chemotherapy. Edeiken-Moore et al. [9] described a similar method of marking tumor beds with metallic markers using a 15-gauge needle. The method outlined in our report may help obtain this information with the added benefit of using an 18-gauge needle for placement.

In summary, marking the tumor bed before the institution of chemotherapy can now be relatively easily accomplished and may offer some additional insight into tumor biology.


References
Top
Introduction
Subjects and Methods
Discussion
References
 

  1. Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin I. Surgical adjuvant chemotherapy: results of one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 1978;41:2088-2098[Medline]
  2. Fisher B, Carbone P, Economou SG, et al. Phenylalanine mustard (L-PAM) in the management of primary breast cancer: report of early findings. N Engl J Med 1975;292:117-122[Abstract]
  3. Bonnadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-410[Abstract]
  4. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-129[Medline]
  5. Bonnadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-1545[Abstract/Free Full Text]
  6. Powles T, Hickish T, Ashley AS, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-552[Abstract/Free Full Text]
  7. Feldman L, Hortobagyi G, Buzdar A, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-2581[Abstract/Free Full Text]
  8. Vinnicombe S, MacVicar D, Guy R, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy with pathologic correlation. Radiology 1996;198:333-340[Abstract/Free Full Text]
  9. Edeiken-Moore BS, Fornage, BD, Holmes FA. A preliminary report of sonographically guided implantation of metallic markers to permanently localize the tumor bed in patients with breast cancer receiving preoperative chemotherapy (abstr). AJR 1997;168[suppl]:98

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
E. P. Mamounas
Tailoring Loco-Regional Therapy with Neoadjuvant Chemotherapy: Another Step in the Right Direction
Ann. Surg. Oncol., October 1, 2004; 11(10): 888 - 891.
[Full Text] [PDF]


Home page
Br. J. Radiol.Home page
R Warren and P Kessar
A method of coil localization for breast lesions seen only on MRI
Br. J. Radiol., June 1, 2001; 74(882): 548 - 551.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
S. W. Phillips, H. Gabriel, C. E. Comstock, and L. A. Venta
Sonographically Guided Metallic Clip Placement After Core Needle Biopsy of the Breast
Am. J. Roentgenol., November 1, 2000; 175(5): 1353 - 1355.
[Full Text] [PDF]


This Article
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braeuning, M. P.
Right arrow Articles by Pisano, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braeuning, M. P.
Right arrow Articles by Pisano, E. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS